Effect on surgical decisions: Ulipristal acetate as key player in Belgian phase IV registration trial

To observe alterations in surgical planning that were due to the use of ulipristal acetate (UPA) 5 mg daily for symptomatic uterine fibroids.

[1]  I. Staboulidou,et al.  Morbidity, fertility and pregnancy outcomes after myoma enucleation by laparoscopy versus laparotomy , 2018, Archives of Gynecology and Obstetrics.

[2]  F. Odejinmi,et al.  Pushing the boundaries of laparoscopic myomectomy: a comparative analysis of peri-operative outcomes in 323 women undergoing laparoscopic myomectomy in a tertiary referral centre , 2017, Gynecological Surgery.

[3]  J. Carlow,et al.  Symptomatic Fibroid Management: Systematic Review of the Literature , 2017, JSLS : Journal of the Society of Laparoendoscopic Surgeons.

[4]  E. Sarıdoğan,et al.  Laparoscopic Myomectomy: A Single-center Retrospective Review of 514 Patients. , 2017, Journal of minimally invasive gynecology.

[5]  H. Fernandez,et al.  Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results. , 2017, European journal of obstetrics, gynecology, and reproductive biology.

[6]  D. Timmerman,et al.  Ultrasonography in the prediction of complications during and after uterine myomectomy , 2016, Gynecological Surgery.

[7]  D. Barlow,et al.  Long-term medical management of uterine fibroids with ulipristal acetate. , 2016, Fertility and sterility.

[8]  I. Osterloh,et al.  Long-term treatment of uterine fibroids with ulipristal acetate ☆. , 2014, Fertility and sterility.

[9]  I. Osterloh,et al.  Ulipristal acetate versus placebo for fibroid treatment before surgery. , 2012, The New England journal of medicine.

[10]  I. Osterloh,et al.  Ulipristal acetate versus leuprolide acetate for uterine fibroids. , 2012, The New England journal of medicine.

[11]  E. Wallach,et al.  Uterine Myomas: An Overview of Development, Clinical Features, and Management , 2004, Obstetrics and gynecology.